Transforming growth factor beta-2 (TGF-β2) mRNA and Plasmodium falciparum heme detoxification pathway

Transforming growth factor beta-2 (TGF-β2) mRNA and the Plasmodium falciparum heme detoxification pathway are two distinct therapeutic targets grouped together in this entry. TGF-β2 is a potent immunosuppressive cytokine that promotes tumor progression and metastasis in cancers such as high-grade glioma; its mRNA is targeted by antisense oligonucleotides like trabedersen to downregulate protein production and restore anti-tumor immune responses (Source: PubMed, PMID: 18450145). The Plasmodium falciparum heme detoxification pathway is a vital metabolic process in which the malaria parasite converts toxic free heme, released during hemoglobin digestion, into insoluble hemozoin crystals (Source: Nature Reviews Microbiology, doi:10.1038/nrmicro2222). Traditional antimalarial drugs, including chloroquine and quinine, target this pathway by binding to heme or the crystal surface, preventing detoxification and leading to parasite death (Source: PubChem). Because these targets belong to different organisms and disease states, they are not typically addressed by a single therapeutic agent. This composite entry likely reflects a data integration error rather than a unified biological target.

Other names

TGFB2 mRNATransforming growth factor beta-2 antisense targetHeme biocrystallization pathwayHemozoin formation pathwayFerriprotoporphyrin IX detoxification

This entry involves two distinct mechanisms: antisense oligonucleotides (e.g., trabedersen) bind to TGF-beta 2 mRNA to prevent the translation of the TGF-beta 2 protein, while quinoline antimalarials (e.g., chloroquine) inhibit the polymerization of toxic free heme into non-toxic hemozoin crystals within the malaria parasite's food vacuole.